Using advanced imaging to personalize radiotherapy for skull base chordoma
A Technical Framework for Combining Multi-parametric Imaging With Advanced Modelling in Personalized Radiotherapy
This study is testing whether advanced imaging can help tailor radiotherapy treatments for patients with skull base chordoma to improve their outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CNAO National Center of Oncological Hadrontherapy Academic / other |
| Drugs / interventions | Immunotherapy |
| Locations | 1 site (Pavia, Pv) |
| Trial ID | NCT05888064 on ClinicalTrials.gov |
What this trial studies
This study involves collecting both retrospective and prospective imaging data from patients with skull base chordoma who have undergone particle therapy. The aim is to derive imaging biomarkers that, when combined with advanced mathematical models, can predict treatment outcomes on multiple scales. Data will include CT, MRI, and dose maps, along with relevant clinical information, and will be securely stored and shared between the National Center for Oncological Hadrontherapy and Politecnico di Milano. The ultimate goal is to enhance the personalization of radiotherapy treatments for these patients.
Who should consider this trial
Good fit: Ideal candidates include patients with a confirmed diagnosis of skull base chordoma who are undergoing particle therapy with curative intent.
Not a fit: Patients with metastatic disease, palliative treatment needs, or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and tailored radiotherapy treatments for patients with skull base chordoma.
How similar studies have performed: While the approach of integrating imaging biomarkers with mathematical models is innovative, similar studies have shown promise in other cancer types, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with histologically confirmed diagnosis of chordoma of the skull base * Particle therapy with curative intent * Karnofsky Performance status greater than or equal to 60 * Patients with macroscopic disease detectable at pre-radiotherapy imaging * Patients undergoing PT with standardized treatment procedures * Patients who have signed the written informed consent for research Exclusion Criteria: * Metastatic disease * Palliative treatment * Other malignancies with disease-free interval \< 5 years (excepting pre- cancerous lesions) * Pregnancy * Simultaneous CHT or Immunotherapy * Extensive metal instrumentation/implants * Patients with autoimmune diseases (ADs) -including collagen-vascular (CVD) and inflammatory bowel (IBD)
Where this trial is running
Pavia, Pv
- Cnao — Pavia, Pv, Italy (Recruiting)
Study contacts
- Principal investigator: Alberto Iannalfi, MD — CNAO National Center of Oncological Hadrontherapy
- Study coordinator: Alberto Iannalfi, MD
- Email: alberto.iannalfi@cnao.it
- Phone: 0382078501
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.